

Personalized Biopsy Schedules using Joint Models

Anirudh Tomer, Dimitris Rizopoulos, Ewout Steyerberg, Monique Roobol
October 25, 2017

Active Surveillance

- To avoid over-treatment men with low grade cancers are advised to enroll AS programs
- Decision to start active treatment is based on biopsies
 - reliable
 - painful \Rightarrow cause anxiety
 - complications (inflammation, hematuria)
- High non-compliance rates \Rightarrow compromised effectiveness of AS

Active Surveillance (cont'd)

- Currently, AS programs primarily use fixed schedules
 - yearly (aggressive)
 - every 3 years
 - ...
- Unnecessary biopsies in patients who progress slowly

PRIAS Study


- AS program in which men with early prostate cancer are managed by a follow-up strategy
 - 5267 patients
 - biopsies at baseline, 1, 4, 7 and 10 years
 - or yearly after PSA doubling within a year
- Outcomes of interest:
 - time to Gleason score reclassification (from 6 to ≥ 7)
 - longitudinal PSA measurements

PRIAS Study (cont'd)

Outcome:

survival ▼

Kaplan-Meier Estimate



PRIAS Study (cont'd)

How to better plan biopsies?

- In steps:
 - *How the longitudinal PSA is related to Gleason reclassification?*
 - *How to combine previous PSA measurements and biopsies to predict reclassification?*
 - *When to plan the next biopsy?*

Time-varying Covariates

- To answer these questions we need to link
 - the time to Gleason reclassification (survival outcome)
 - the PSA measurements (longitudinal outcome)
- Biomarkers are *endogenous* time-varying covariates
 - their future path depends on previous events
 - standard time-varying Cox model not appropriate



Time-varying Covariates (cont'd)

To account for endogeneity we use the framework of

Joint Models for Longitudinal & Survival Data

The Basic Joint Model

Measurements:



The Basic Joint Model (cont'd)

- We need some notation
 - T_i^* the true reclassification time
 - T_i^L last biopsy time point Gleason Score was < 7
 - T_i^R first biopsy time point Gleason Score was ≥ 7
 - $T_i^R = \infty$ for patients who haven't been reclassified yet
 - \mathbf{y}_i vector of longitudinal PSA measurements
 - $\mathcal{Y}_i(t) = \{y_i(s), 0 \leq s < t\}$

The Basic Joint Model (cont'd)

- Formally, we have

$$\left\{ \begin{array}{lcl} h_i(t) & = & h_0(t) \exp\{\gamma^\top \mathbf{w}_i + \alpha \eta_i(t)\} \\ y_i(t) & = & \eta_i(t) + \varepsilon_i(t) \\ & = & \mathbf{x}_i^\top(t) \beta + \mathbf{z}_i^\top(t) \mathbf{b}_i + \varepsilon_i(t) \\ & & \mathbf{b}_i \sim \mathcal{N}(\mathbf{0}, \mathbf{D}), \quad \varepsilon_i(t) \sim \mathcal{N}(0, \sigma^2) \end{array} \right.$$

The Basic Joint Model (cont'd)

- The longitudinal and survival outcomes are jointly modeled

$$p(y_i, T_i^L, T_i^R) = \int p(y_i \mid b_i) \times \{S(T_i^L \mid b_i) - S(T_i^R \mid b_i)\} \times p(b_i) db_i$$

- the random effects b_i explain the interdependencies



Functional Form

- Biomarker's rate of change
 - fast increasing PSA indicative of progression

$$h_i(t) = h_0(t) \exp\{\gamma^\top \mathbf{w}_i + \alpha_1 \eta_i(t) + \alpha_2 \eta'_i(t)\}$$

where $\eta'_i(t) = \frac{d}{dt} \eta_i(t)$

Functional Form (cont'd)



PRIAS Study Analysis

- PSA growth

$$\left\{ \begin{array}{l} \log_2(PSA) = \eta_i(t) + \varepsilon_i(t) \\ \quad = \beta_0 + \sum_{k=1}^3 \beta_k NS_k(t, \nu) + \beta_4 \text{Age} + \beta_5 \text{Age}^2 \\ \quad + b_{i0} + \sum_{k=1}^2 b_{ik} NS_k(t, \nu) + \varepsilon_i(t) \\ \mathbf{b}_i \sim \mathcal{N}(\mathbf{0}, \mathbf{D}), \quad \varepsilon_i(t) \sim \mathcal{N}(0, \sigma^2) \end{array} \right.$$

PRIAS Study Analysis (cont'd)

- Risk of reclassification


$$h_i(t) = h_0(t) \exp \left\{ \gamma_1 \text{Age} + \gamma_2 \text{Age}^2 + \alpha_1 \eta_i(t) + \alpha_2 \frac{d\eta_i(t)}{dt} \right\}$$

where

- $\eta_i(t)$ log2(PSA) current value
- $\frac{d\eta_i(t)}{dt}$ log2(PSA) velocity

PRIAS Study Analysis (cont'd)

- Results



Info From a New Patient

- Suppose a new patient j comes in
- What is the available information
 - last biopsy: $T_j^* > t$
 - PSA measurements: $\mathcal{Y}_j(s) = \{y_j(t_{jl}); 0 \leq t_{jl} \leq s, l = 1, \dots, n_j\}$
 - typically $s \geq t$
 - \mathcal{D}_n sample on which the joint model was fitted

Info From a New Patient (cont'd)

- **Aim:** We want to combine all this information into a single tool to predict Gleason upgrade
- Posterior Predictive Distribution (PPD)

$$p\{T_j^* \mid T_j^* > t, \mathcal{Y}_j(s), \mathcal{D}_n\}$$

Two Avenues to Plan Biopsies

- What is the best guess on when Gleason upgrade will occur?
- **Option 1:** Theory and intuition suggest a measure of central tendency, e.g.,
 - u = mean of PPD
 - u = median of PPD
- **Option 2:** Risk-based approach, select $u > t$ such that

$$\Pr(T_j^* < u \mid T_j^* > t, \mathcal{Y}_j(s), \mathcal{D}_n) = \kappa, \quad 0 \leq \kappa \leq 1$$

Two Avenues to Plan Biopsies (cont'd)

- Selection of κ for Option 2
- Risk urologists are willing to take
 - e.g., risk of reclassification should be less than 10%
 - *often no clear consensus*
- Data-driven approach based on ROC analysis in \mathcal{D}_n
 - F1 score (https://en.wikipedia.org/wiki/F1_score), Youden's J (https://en.wikipedia.org/wiki/Youden%27s_J_statistic), ...
 - time-varying thresholds $k(t)$, $0 \leq t \leq t_{max}$

Simulations - Design

- We evaluated both approaches in simulations
- Data were simulated from the model fitted to PRIAS
 - value + velocity of PSA
 - 3 subgroups, early, mid and late progression

Simulations - Design (cont'd)

- Objective evaluation - each simulated dataset split in two parts
 - *training*: to fit the model
 - *test*: to apply the procedure for selecting biopsy times
- Performance judged based on
 - effort required to find reclassification \Rightarrow # Biopsies
 - how much we overshoot \Rightarrow Offset


Simulation - Results

Statistic: Offset ▼

Method: PRIAS Annual Median
Dyn.Risk
Median + Dyn.Risk

Period ☒

Zoom-in ☒



Online App

- We have created an online app to facilitate the whole procedure:

https://emcbiostatistics.shinyapps.io/Dynamic_Predictions/
(https://emcbiostatistics.shinyapps.io/Dynamic_Predictions/)

Discussion

- Things to improve
 - account for miss-classification
 - include DRE
- Preprint available at: <https://arxiv.org/abs/1711.00285>
(<https://arxiv.org/abs/1711.00285>)
- Software: available in **JMbayes** on CRAN & GitHub
 - <https://cran.r-project.org/package=JMbayes> (<https://cran.r-project.org/package=JMbayes>)
 - <https://github.com/drizopoulos/JMbayes>
(<https://github.com/drizopoulos/JMbayes>)

Thank you for your attention!

<http://www.drizopoulos.com/> (http://www.drizopoulos.com/)